EUVIMEDEUVIMED entdecken
Crossref

Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction

Yang Yang, Meiqin Xu, Ke Wang, Liang Xia, Qianchen Ning, Xintong Wu, Xinyue Zang, Fangfang Lai, Xiaoguang Chen, Zhiqiang Feng

Bioorganic & Medicinal Chemistry · 2025

DOI: 10.1016/j.bmc.2025.118366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2025. Verfasst von Yang Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; College of Medicine, Linyi Un…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen, Antineoplastic Agents, Phenyl Ethers. Die Arbeit nennt 36 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting the PD-1/PD-L1 immune checkpoint pathway with small molecules has exhibited great promise. Herein, to develop the inhibitors with good activity, pharmacokinetic properties and druggability, a novel series of halogens substituted derivatives at the 2-position of the biphenyl group were synthesized, screened, and their inhibitory activity against the PD-1/PD-L1 protein-protein interaction (PPI) was evaluated through a HTRF assay. Among them, YPD-29B exhibited potent activity with IC50 value of less than 1 pM. Furthermore, the PBMC-based PD-1/PD-L1 blockade bioassay revealed that YPD-29B could inhibit the PD-1/PD-L1 interaction and restore T-cell function with the concentration of 10 nM at the cellular level and with the IC50 value of 0.18 nM. However, the poor solubility of YPD-29B limited the evaluation of antitumor activity in vivo. Thus, the prodrug, sodium salt and hydrochloride of YPD-29B were designed and synthesized to conduct the animal experiments, revealing the obvious anti-melanoma activity of YPD-29B-Na with TGI of 64.11 % and weak toxicity on the blood index and the body weight compared with the positive control CTX. T lymphocyte infiltration markedly increased in tumors of the different treated groups, suggesting the activation of the immune system. Besides, molecular docking verified the rationality of the design. IMMH-010, as a prodrug of YPD-29B has been approved for clinical phase I by NMPA. We hope these above results could offer a novel perspective for the development of PD-1/PD-L1 small molecule inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorB7-H1 AntigenAntineoplastic AgentsPhenyl EthersDrug DiscoveryImmune Checkpoint InhibitorsHumansAnimalsStructure-Activity RelationshipMiceMolecular StructureDrug Screening Assays, AntitumorDose-Response Relationship, DrugMolecular Docking SimulationCell ProliferationCell Line, TumorProtein Binding

Stichwörter der Autor:innen

Cancer immunotherapyImmune checkpointPD-1/PD-L1Small molecules inhibitors

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanPDCD1 protein, humanAntineoplastic AgentsPhenyl EthersImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; College of Medicine, Linyi University, Linyi 276000, China.
  • Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Mate…
  • Department of Pharmacology, State Key laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100…
  • College of Medicine, Linyi University, Linyi 276000, China.

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Y., Xu, M., Wang, K., Xia, L., Ning, Q., Wu, X., Zang, X., Lai, F., Chen, X., & Feng, Z. (2025). Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2025.118366

Vancouver

Yang Y, Xu M, Wang K, Xia L, Ning Q, Wu X, et al. Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Bioorganic & Medicinal Chemistry. 2025. doi:10.1016/j.bmc.2025.118366

BibTeX
@article{Yang2025,
  author = {Yang, Yang and Xu, Meiqin and Wang, Ke and Xia, Liang and Ning, Qianchen and Wu, Xintong and Zang, Xinyue and Lai, Fangfang and Chen, Xiaoguang and Feng, Zhiqiang},
  title = {Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2025},
  doi = {10.1016/j.bmc.2025.118366}
}
Kostenlos starten →